Friday, Jan 16, 2004
South San Francisco, Calif. -- January 16, 2004 --Genentech, Inc. (NYSE: DNA) today announced three senior appointments in the company's Development, Commercial and Manufacturing organizations: Hal Barron's promotion to senior vice president, Development; Varun Nanda's promotion to vice president, Sales and Marketing; and Patrick Yang's appointment to vice president, South San Francisco Manufacturing and Engineering.
Hal Barron, M.D.
Senior Vice President
Hal Barron joined Genentech in 1996 as a clinical scientist. During the next several years, he held positions as associate director and director of Cardiovascular Research and senior director of the Biotherapeutics group within Medical Affairs. In May 2002, he was promoted to vice president of Medical Affairs.
Barron will lead the newly formed Development organization that is being created by combining Genentech's Medical Affairs and Development Sciences departments. The Development organization will be responsible for pre-clinical, clinical, and post-approval activities. In his new role, Barron will continue to report to Susan D. Hellmann, M.D., M.P.H., Genentech's executive vice president, Development and Product Operations, and chief medical officer.
"Hal has made significant contributions to Genentech throughout his tenure here," said Hellmann. "I am confident that his contributions will continue as he takes on enhanced responsibilities overseeing this larger organization."
Barron received his medical degree from Yale University and holds a Bachelor of Science degree from Washington University.
Sales and Marketing - Avastin
Varun Nanda joined Genentech in 1997 as director of Endocrinology and subsequently was responsible for the launch planning of Xolair® (Omalizumab). Since 2001, he held the position of senior director of sales and marketing for the Solid Tumor Oncology Franchise. In that position, he was responsible for Herceptin® (Trastuzumab) and the prelaunch planning for Avastin (bevacizumab) and Tarceva (erlotinib HCl). Nanda reports to Ian Clark, senior vice president and general manager, BioOncology.
"This is a pivotal role for Genentech as we continue with our launch preparations for Avastin, which, if approved, could be a new treatment option for patients with metastatic colorectal cancer," said Clark. "I anticipate great success for this important part of our business under Varun's leadership."
Prior to joining Genentech, Nanda was director of brand management at Novo Nordisk A/S. Nanda holds a Bachelor of Engineering degree from Delhi College of Engineering and a Master of Business Administration from Eastern Illinois University.
Patrick Yang, Ph.D.
South San Francisco Manufacturing and Engineering
Patrick Yang joins Genentech from Merck & Co., where he held several leadership roles in Merck's Manufacturing Division over the past 11 years. Most recently, he held the position of vice president, Supply Chain Management. In this role, he led the worldwide materials management, strategic planning and manufacturing support functions for Merck's 34 plants. Previous to that, he was Merck's vice president, Asia/Pacific Manufacturing Operations. He will report to David Ebersman, senior vice president, Product Operations.
"Pat brings a wealth of experience in manufacturing operations to Genentech," said Ebersman. "With more than 20 years of leadership and hands-on experience in manufacturing and engineering management, he is ideally suited to help us achieve the aggressive manufacturing goals required to support our growth."
Prior to joining Merck in 1992, Yang spent 12 years at General Electric, serving in several research, engineering, technology and manufacturing management roles.
Yang holds a Bachelor of Science degree from the National Chiaotung University in Taiwan, a Master of Science in Electrical Engineering from the University of Cincinnati, and a doctorate in Electrical Engineering/Computer Science from Ohio State.
Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes biotherapeutics for significant unmet medical needs. Seventeen of the currently approved biotechnology products originated from or are based on Genentech science. Genentech manufactures and commercializes 12 biotechnology products in the United States. The company has headquarters in South San Francisco, California and is traded on the New York Stock Exchange under the symbol DNA. For additional information about the company, please visit http://www.gene.com.